CN105560550A - 一种防治蛋鸡脂肪肝综合征的药物组合物及其制备方法 - Google Patents
一种防治蛋鸡脂肪肝综合征的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN105560550A CN105560550A CN201610028356.5A CN201610028356A CN105560550A CN 105560550 A CN105560550 A CN 105560550A CN 201610028356 A CN201610028356 A CN 201610028356A CN 105560550 A CN105560550 A CN 105560550A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- vitamin
- western medicine
- fatty liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 51
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 24
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 23
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 23
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 23
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 229940079593 drug Drugs 0.000 title claims description 6
- 239000000203 mixture Substances 0.000 title abstract description 5
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims abstract description 17
- 235000019743 Choline chloride Nutrition 0.000 claims abstract description 17
- 229960003178 choline chloride Drugs 0.000 claims abstract description 17
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims abstract description 17
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 15
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 15
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 15
- 229960000367 inositol Drugs 0.000 claims abstract description 15
- 229930182817 methionine Natural products 0.000 claims abstract description 15
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 13
- 239000008103 glucose Substances 0.000 claims abstract description 13
- 239000009636 Huang Qi Substances 0.000 claims abstract description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229930003270 Vitamin B Natural products 0.000 claims abstract description 10
- 239000010231 banlangen Substances 0.000 claims abstract description 10
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 10
- 239000011720 vitamin B Substances 0.000 claims abstract description 10
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 5
- 229940046009 vitamin E Drugs 0.000 claims abstract description 5
- 239000011709 vitamin E Substances 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 229940088594 vitamin Drugs 0.000 claims description 11
- 229930003231 vitamin Natural products 0.000 claims description 11
- 235000013343 vitamin Nutrition 0.000 claims description 11
- 239000011782 vitamin Substances 0.000 claims description 11
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 11
- 229930003779 Vitamin B12 Natural products 0.000 claims description 4
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 4
- 229960004452 methionine Drugs 0.000 claims description 4
- 235000006109 methionine Nutrition 0.000 claims description 4
- 235000019163 vitamin B12 Nutrition 0.000 claims description 4
- 239000011715 vitamin B12 Substances 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 10
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 abstract 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 15
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 6
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 6
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 230000006378 damage Effects 0.000 description 3
- 230000002008 hemorrhagic effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 2
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 2
- UPCWCCRFMPIOAP-UHFFFAOYSA-N Hydroxytanshinone Chemical compound C1=CC(C(CCC2O)(C)C)=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 UPCWCCRFMPIOAP-UHFFFAOYSA-N 0.000 description 2
- 231100000678 Mycotoxin Toxicity 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002636 mycotoxin Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XDUXBBDRILEIEZ-LJQANCHMSA-N (6s)-6-(hydroxymethyl)-1,6-dimethyl-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCC[C@](C)(CO)C3=CC=C2C2=C1C(C)=CO2 XDUXBBDRILEIEZ-LJQANCHMSA-N 0.000 description 1
- HARGZZNYNSYSGJ-UHFFFAOYSA-N 1,2 dihydrotanshinquinone Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)CO1 HARGZZNYNSYSGJ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- HARGZZNYNSYSGJ-JTQLQIEISA-N Dihydrotanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2[C@@H](C)CO1 HARGZZNYNSYSGJ-JTQLQIEISA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- XDUXBBDRILEIEZ-UHFFFAOYSA-N Tanshinone IIB Natural products O=C1C(=O)C2=C3CCCC(C)(CO)C3=CC=C2C2=C1C(C)=CO2 XDUXBBDRILEIEZ-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- XLIJUKVKOIMPKW-BTVCFUMJSA-N [O].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O Chemical compound [O].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XLIJUKVKOIMPKW-BTVCFUMJSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000006567 cellular energy metabolism Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- KXNYCALHDXGJSF-UHFFFAOYSA-N dihydroisotanshinone I Natural products CC1=CC=CC2=C(C(C=3OCC(C=3C3=O)C)=O)C3=CC=C21 KXNYCALHDXGJSF-UHFFFAOYSA-N 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种兽药,尤其是一种防治蛋鸡脂肪肝综合征的药物组合物及其制备方法,所述的防治蛋鸡脂肪肝综合征的药物组合物,包括中药组分和西药组分,中药组分与西药组分的重量比为2:1;所述中药组分按照重量份计,包括丹参25-35份、五味子18-22份、当归8-12份、黄芪8-12份、柴胡8-12份、板蓝根8-12份和甘草8-12份;所述西药组分按照重量份计,包括氯化胆碱80-120份、蛋氨酸100-150份、维生素E1.8-2.2份、维生素B120.001-0.0015份、肌醇80-120份和葡萄糖150-200g份。本发明采用西药复合物和丹参等中药的相互配合,提高了治疗效果。
Description
技术领域
本发明涉及一种兽药,尤其是一种防治蛋鸡脂肪肝综合征的药物组合物及其制备方法。
背景技术
在蛋鸡生产中,病毒、细菌、寄生虫、霉菌毒素、药物中毒、热应激、脂肪过度沉积等许多因素都可造成肝损伤,从而促发蛋鸡脂肪肝综合症。蛋鸡脂肪肝综合症又叫脂肪肝出血综合症,是肝脏发生脂肪变性和伴有出血特征的一种营养代谢性疾病。长期饲喂过量饲料,摄入能量过多;饲料中霉菌毒素超标,过量使用伤肝的药物,病原微生物感染的因素均可导致脂肪肝。治疗时每千克饲料中加入1克氯化胆碱、1.2克蛋氨酸、20国际单位维生素E、0.012毫克维生素B12、1克肌醇、0.3毫克生物素、0.1克维生素C,连喂2周。该治疗方法的不足之处是需要增加保护动物肝脏,改善肝脏微循环,促使肝脏修复的药物。
公开CN101653519A,发明名称:防治鸡脂肪肝出血综合症的中药组合物及其制备方法,本发明涉及一种防治鸡脂肪肝出血综合症的中药组合物,其特征是:由下列药物组成,按重量份数计,龙胆1-4份、车前草1-3份、柴胡1-3份、当归1-3份、桅子1-3份、生地1-4份、甘草1-2份、黄芪1-3份、泽泻1-4份、关木通1-3份;其制备方法,按以下步骤进行:(1)按重量份数称龙胆1-4份、车前草1-3份、柴胡1-3份、当归1-3份、桅子1-3份、生地1-4份、甘草1-2份、黄芪1-3份、泽泻1-4份、关木通1-3份为原料;(2)将上述中药粉碎,过200-400目振荡筛,混匀,即成。该发明的有益效果:本发明药物不但疗效突出,并且无药残、无毒副作用、无耐药性问题。但是该方法治疗效果不好,治疗后蛋鸡的产蛋率恢复较慢。
发明内容
本发明提供了一种防治蛋鸡脂肪肝综合征的药物组合物及其制备方法,解决了现有西药治疗方法对鸡肝脏有损伤,需要增加保护动物肝脏,改善肝脏微循环,促使肝脏修复的药物,中药方法疗效一般,治疗时间长等问题。
为解决上述技术问题,本发明采用的技术方案为:
一种防治蛋鸡脂肪肝综合征的药物组合物,包括中药组分和西药组分,中药组分与西药组分的的重量比为2:1;
所述中药组分按照重量份计,包括丹参25-35份、五味子18-22份、当归8-12份、黄芪8-12份、柴胡8-12份、板蓝根8-12份和甘草8-12份;
所述西药组分按照重量份计,包括氯化胆碱80-120份、蛋氨酸100-150份、维生素E1.8-2.2份、维生素B120.001-0.0015份、肌醇80-120份和葡萄糖150-200份。
进一步,本发明的一种优选方案为:所述中药组分按照重量份计,包括丹参30份、五味子20份、当归10份、黄芪10份、柴胡10份、板蓝根10份和甘草10份。
进一步,本发明的一种优选方案为:所述西药组分按照重量份计,包括氯化胆碱100份、蛋氨酸120份、维生素E2份、维生素B120.0012份、肌醇100份和葡萄糖180份。
本发明的防治蛋鸡脂肪肝综合征的药物组合物的制备方法,
(1)中药组分的制备:按照重量称取各种中药材,烘干,粉碎混合成粉剂,制成中药组分;
(2)西药组分的制备:分别称取氯化胆碱、蛋氨酸、维生素E、维生素B12、肌醇、葡萄糖,粉碎,过80-100目筛,制成药物组合物中的西药部分;
(3)将中药组分和西药组分分别包装,既得防治蛋鸡脂肪肝综合征的药物组合物。
进一步,本发明的一种优选方案为:所述的烘干温度为60-65℃,时间为2-3h。
本发明的有益效果:
本发明选择丹参、五味子、当归、板蓝根、黄芪、柴胡、甘草、氯化胆碱、蛋氨酸、维生素E、维生素B12、肌醇等12种药物构成的。丹参味苦,性微寒,归心、肝二经。丹参的水提液中有丹参素,丹参素具有钙拮抗、清除自由基、保护线粒体以及抗氧化、抑制心肌肥大、抗血栓形成等作用,这有利于保护心肌,维持心脏正常功能,促进肉鸡生长。丹参已被证实具有明显的抗肝脏纤维化的作用,丹参素可以在一定范围内呈剂量依赖性地直接刺激体外培养小鼠肝细胞的增殖,表明丹参素还有促进肝细胞修复再生的作用。丹参素对细胞因子活化内皮细胞有抑制作用,从而有利于保护血管内皮,减少白细胞的黏附。丹参素能显著改善缺氧缺糖损伤所致的线粒体氧化磷酸化功能障碍,调节细胞能量代谢的作用,使LDH的释放、细胞Ca2+水平、细胞凋亡及坏死的百分率均明显降低,对缺血性损伤的神经细胞有保护作用。由于丹参具有改善心脏、肝脏、神经等的功能,提高蛋鸡成活率原因。丹参酮、隐丹参酮、丹参酸、原儿茶酸等都具有很强的抗脂质过氧化和清除自由基作用,对动物机体的组织损伤具有明显地保护作用,对动物的健康具有促进作用。隐丹参酮、二氢丹参酮、羟基丹参酮ⅡA、丹参酸丹酯及丹参酮ⅡB对金黄色葡萄球菌及其耐药菌株均有抑菌作用。
本发明注重了丹参等中药对肝脏的修复,解毒,和中,补血养血,补脾益气,疏肝胆之气,增加蛋鸡的抗病力。五味子具有保护动物肝脏,降低转氨酶,增强免疫力,抗热应激,抗氧化作用及改善肉质等作用。当归具有补血养血,活血止痛,润肠通便,理气和血等功能。
氯化胆碱为亲脂性物质,系卵磷脂的组成部分,与正常脂肪代谢和运转有关,能与肝内积存的脂肪作用,使变为易吸收的磷脂,又为供给机体进行生化过程所需甲基的重要来源。氯化胆碱等西药复合物和丹参等中药的相互配合,提高了治疗效果。
具体实施方式
下面结合实施例对本发明的具体实施方式进行描述,以便更好的理解本发明。
实施例1
一种防治蛋鸡脂肪肝综合征的药物组合物,包括中药组分和西药组分,中药组分与西药组分的的重量比为2:1;
所述中药组分按照重量份计,包括丹参30份、五味子20份、当归10份、黄芪10份、柴胡10份、板蓝根10份和甘草10份;
所述西药组分按照重量份计,包括氯化胆碱100份、蛋氨酸120份、维生素E2份、维生素B120.0012份、肌醇100份和葡萄糖180份;
其制备方法:
(1)中药组分的制备:按照重量称取各种中药材,烘干,粉碎混合成粉剂,制成中药组分;
(2)西药组分的制备:分别称取氯化胆碱、蛋氨酸、维生素E、维生素B12、肌醇、葡萄糖,粉碎,过80-100目筛,制成药物组合物中的西药部分;
(3)将中药组分和西药组分分别包装,即得防治蛋鸡脂肪肝综合征的药物组合物。
实施例2
与实施例1基本相同不同之处在于:所述中药组分按照重量份计,包括丹参25份、五味子22份、当归12份、黄芪8份、柴胡8份、板蓝根12份和甘草12份。
实施例3
与实施例1基本相同不同之处在于:所述中药组分按照重量份计,包括丹参35份、五味子18份、当归8份、黄芪12份、柴胡12份、板蓝根8份和甘草8份。
实施例4
与实施例1基本相同不同之处在于:所述西药组分按照重量份计,包括氯化胆碱80份、蛋氨酸100份、维生素E1.8份、维生素B120.001份、肌醇80份和葡萄糖150份。
实施例5
与实施例2基本相同不同之处在于:所述西药组分按照重量份计,包括氯化胆碱100份、蛋氨酸150份、维生素E2.2份、维生素B120.0015份、肌醇100份和葡萄糖200份。
实施例6
与实施例3基本相同不同之处在于:所述西药组分按照重量份计,包括氯化胆碱120份、蛋氨酸120份、维生素E2份、维生素B120.0012份、肌醇120份和葡萄糖180份。
药效研究
对比例1采用西药,组成为包括氯化胆碱100份、蛋氨酸120份、维生素E1.5-2份、维生素B120.0012份、肌醇100份和葡萄糖180份。
对比例2采用中药组成为包括丹参30份、五味子20份、当归10份、黄芪10份、柴胡10份、板蓝根10份和甘草10份。
实验例采用实施例1-6所制备的药物组合物。
选择800只确诊为脂肪肝综合征的蛋鸡,随机分组,每组100只。对比例1采用每100千克饲料中加入对比例1的西药500克,对比例2采用每100千克饲料中加入对比例2的中药1000g,实验例1采用每100千克饲料中加入1500g实施例1-6所制备的药物组合物,连喂2周,具体结果见下表。
实验结果
以上所述是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也视为本发明的保护范围。
Claims (5)
1.一种防治蛋鸡脂肪肝综合征的药物组合物,其特征在于:包括中药组分和西药组分,中药组分与西药组分的的重量比为2:1;
所述中药组分按照重量份计,包括丹参25-35份、五味子18-22份、当归8-12份、黄芪8-12份、柴胡8-12份、板蓝根8-12份和甘草8-12份;
所述西药组分按照重量份计,包括氯化胆碱80-120份、蛋氨酸100-150份、维生素E1.8-2.2份、维生素B120.001-0.0015份、肌醇80-120份和葡萄糖150-200份。
2.根据权利要求1所述的一种防治蛋鸡脂肪肝综合征的药物组合物,其特征在于:所述中药组分按照重量份计,包括丹参30份、五味子20份、当归10份、黄芪10份、柴胡10份、板蓝根10份和甘草10份。
3.根据权利要求1所述的一种防治蛋鸡脂肪肝综合征的药物组合物,其特征在于:所述西药组分按照重量份计,包括氯化胆碱100份、蛋氨酸120份、维生素E2份、维生素B120.0012份、肌醇100份和葡萄糖180份。
4.一种如权利要求1-3任一项所述的防治蛋鸡脂肪肝综合征的药物组合物的制备方法,其特征在于:
(1)中药组分的制备:按照重量称取各种中药材,烘干,粉碎混合成粉剂,制成中药组分;
(2)西药组分的制备:分别称取氯化胆碱、蛋氨酸、维生素E、维生素B12、肌醇、葡萄糖,粉碎,过80-100目筛,制成药物组合物中的西药部分;
(3)将中药组分和西药组分分别包装,既得防治蛋鸡脂肪肝综合征的药物组合物。
5.根据权利要求4所述的一种所述的防治蛋鸡脂肪肝综合征的药物组合物的制备方法,其特征在于:所述的烘干温度为60-65℃,时间为2-3h。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610028356.5A CN105560550A (zh) | 2016-01-16 | 2016-01-16 | 一种防治蛋鸡脂肪肝综合征的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610028356.5A CN105560550A (zh) | 2016-01-16 | 2016-01-16 | 一种防治蛋鸡脂肪肝综合征的药物组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105560550A true CN105560550A (zh) | 2016-05-11 |
Family
ID=55871563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610028356.5A Pending CN105560550A (zh) | 2016-01-16 | 2016-01-16 | 一种防治蛋鸡脂肪肝综合征的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105560550A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106387477A (zh) * | 2016-09-30 | 2017-02-15 | 安徽华澳生物技术有限公司 | 一种防治产蛋期蛋鸡脂肪肝综合征的饲料添加剂 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1879845A (zh) * | 2006-04-07 | 2006-12-20 | 成都万芳科技发展有限公司 | 一种具有预防或治疗急慢性肝病的药物组合物 |
CN102188486A (zh) * | 2011-05-10 | 2011-09-21 | 王智森 | 一种防治脂肪肝的药物组合物及其制备方法 |
CN102397335A (zh) * | 2011-11-18 | 2012-04-04 | 青岛绿曼生物工程有限公司 | 一种治疗家禽脂肪肝出血综合征的纯中药组合物及其制备方法 |
CN103446440A (zh) * | 2013-08-29 | 2013-12-18 | 青岛绿曼生物工程有限公司 | 治疗家禽脂肪肝出血综合征的纯中药组合物及其制备方法 |
CN104800746A (zh) * | 2014-01-26 | 2015-07-29 | 天津嘉创生物科技有限公司 | 防治蛋鸡脂肪肝综合征的中药组合物及其制备方法 |
-
2016
- 2016-01-16 CN CN201610028356.5A patent/CN105560550A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1879845A (zh) * | 2006-04-07 | 2006-12-20 | 成都万芳科技发展有限公司 | 一种具有预防或治疗急慢性肝病的药物组合物 |
CN102188486A (zh) * | 2011-05-10 | 2011-09-21 | 王智森 | 一种防治脂肪肝的药物组合物及其制备方法 |
CN102397335A (zh) * | 2011-11-18 | 2012-04-04 | 青岛绿曼生物工程有限公司 | 一种治疗家禽脂肪肝出血综合征的纯中药组合物及其制备方法 |
CN103446440A (zh) * | 2013-08-29 | 2013-12-18 | 青岛绿曼生物工程有限公司 | 治疗家禽脂肪肝出血综合征的纯中药组合物及其制备方法 |
CN104800746A (zh) * | 2014-01-26 | 2015-07-29 | 天津嘉创生物科技有限公司 | 防治蛋鸡脂肪肝综合征的中药组合物及其制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106387477A (zh) * | 2016-09-30 | 2017-02-15 | 安徽华澳生物技术有限公司 | 一种防治产蛋期蛋鸡脂肪肝综合征的饲料添加剂 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101337048B (zh) | 治疗乳腺增生病的药物 | |
CN105028945A (zh) | 一种蛋鸭用饲料及其制备方法 | |
CN102895478A (zh) | 一种温肾助阳的药物组合物及其制备方法 | |
CN105395665A (zh) | 一种预防治疗鱼虾白便的中草药组方 | |
CN105250913A (zh) | 一种治疗蛋鸡脂肪肝综合症的药物组合物 | |
CN103230560B (zh) | 治疗缺血性脑卒中的中药 | |
CN105560550A (zh) | 一种防治蛋鸡脂肪肝综合征的药物组合物及其制备方法 | |
CN102370971B (zh) | 一种治疗鸡痘的复方蜂胶组合物及其制备方法 | |
CN101653519A (zh) | 防治鸡脂肪肝出血综合症的中药组合物及其制备方法 | |
CN103463470A (zh) | 一种鸡用保肝通肾的中药组合物 | |
CN105250767A (zh) | 一种治疗蛋鸡脂肪肝综合症的中药组合物及制备方法 | |
CN105030858A (zh) | 一种锁阳保健片及其制备方法 | |
CN104623535A (zh) | 一种用于产蛋鸡疾病性降蛋治疗的中药组合物及其制备方法和应用 | |
CN104873733B (zh) | 一种抑制雌性甲鱼性腺发育的功能性药饵及其制备方法和投喂方法 | |
CN105362348A (zh) | 一种治疗偏头痛的中药组合物 | |
CN102139028A (zh) | 整肠生药物组合物 | |
CN101716296A (zh) | 一种治疗牛皮癣病的中药丸剂 | |
CN104258009A (zh) | 一种用于防治甲鱼溃烂病的中药 | |
CN103989965A (zh) | 一种治疗乌鸡球虫病的中兽药 | |
CN103990053A (zh) | 一种健脾开胃中兽药 | |
CN104524086B (zh) | 一种用于治疗半滑舌鳎腹水病的中药组合物 | |
CN102397510B (zh) | 一种治疗鸡马立克氏病的复方蜂胶组合物及其制备方法 | |
CN102416107B (zh) | 一种治疗脑血管疾病的药物 | |
CN101954033B (zh) | 一种治疗鸡消化道呼吸道疾病的中药组合物及其制备方法 | |
CN105169341A (zh) | 用于治疗气滞的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160511 |
|
RJ01 | Rejection of invention patent application after publication |